Compounded Oral GLP-1 vs FDA-Approved: What's the Real Difference?

"Not FDA-approved" gets treated as a vague warning label, but for compounded GLP-1s it describes a specific, currently-shifting legal status. Here's what FDA approval actually requires, why compounding was ever legal in the first place, and where the rules stand as of July 2026.

What FDA Approval Actually Means

An FDA-approved drug — Rybelsus, the Wegovy pill, Foundayo, the injectable pens — has gone through a specific formal review: clinical trials at the exact dose and formulation being sold, manufacturing facility inspections, and an ongoing safety-monitoring obligation after approval. The FDA is reviewing that specific product, not just the underlying molecule.

Compounded medications skip all of that. They're prepared by a licensed pharmacy from an individual prescription, under a completely different regulatory framework than new-drug approval.

Why Compounding Was Ever Legal for GLP-1s

Compounding pharmacies are allowed to prepare a version of an FDA-approved drug when the commercial product is in an FDA-declared shortage — this is a longstanding rule, not something invented for GLP-1s. Semaglutide and tirzepatide were both on the FDA's drug shortage list for an extended period starting around 2022, which is what allowed 503A and 503B compounding pharmacies to legally produce and sell compounded versions at scale.

The Shortage Ended — Here's the Actual Timeline

Both shortages have since been resolved, and enforcement discretion (the FDA's grace period for winding down compounding once a shortage ends) has expired for both drugs:

So Is Compounding Illegal Now?

Not entirely — but it's much narrower than the shortage-era free-for-all. Compounding remains legal under a separate, older doctrine: a pharmacy can compound a version of an approved drug for an individual patient if there's a documented, patient-specific reason the commercial product won't work for them — a genuine allergy to an inactive ingredient, or a need for a different dosage form (like a liquid for someone who can't swallow pills). What compounding is not supposed to be, under current FDA guidance, is a mass-marketed, lower-cost alternative to the approved drug sold to anyone who wants it — the FDA's own 2018 guidance calls a compounded product that's essentially identical to an approved drug (same active ingredient, strength, dosage form, and route) an "essentially a copy," which loses the compounding exemption entirely.

Oral and sublingual formulations occupy an interesting position here: because they're a genuinely different dosage form and route than the injectable pen, they have a stronger argument for not being "essentially a copy" than, say, a compounded injectable at the same strength. That said, the FDA has been explicit that it takes issue with providers who market absorption-equivalency claims (implying a compounded oral product works the same as the approved drug) without evidence to support them.

What This Means If You're Choosing Between the Two

• FDA-approved products (Rybelsus, Wegovy Pill, Foundayo) have gone through formal review at the specific dose and formulation you're taking, with ongoing FDA safety monitoring.
• Compounded products are legal to sell, but the FDA hasn't reviewed the specific formulation, and the regulatory environment around them has been getting stricter rather than looser through 2025 and into 2026.
• Neither status is a guarantee of quality on its own — checking a specific pharmacy's licensing (503A/503B), FDA warning letter history, and third-party testing practices matters regardless of which category you're considering.

For the regulatory history specific to oral compounded products — including a real case study of a major provider that had to pull a compounded oral product under FDA pressure — see our FDA's position on compounded oral GLP-1s.